

Index

Note: Page numbers in *italics* – Tables; Page numbers in **bold** – Figures; Page numbers with ‘n’ – Notes

ACE, <i>see</i> angiotensin converting enzyme	amniotic cavity, 50, 55	arterial O ₂ saturation (SaO ₂) altitude impact, 130 <i>see also</i> arterial O ₂ concentration
ACTH, <i>see</i> adrenocorticotrophic hormone	amniotic fluid analysis, 55 antioxidant molecules, 51	assisted reproductive technologies (ART), 35 and Angelman syndrome, 91 and Beckwith-Wiedemann syndrome, 91 <i>in vitro</i> , 23 long term effects, 25 nutritional impact, 23 pre-implantation nutrition, 24 supplementation, 23
activin A, 193 pre-eclampsia, 193 <i>see also</i> pregnancy associated placental protein	amniotic sac, 48	AVM, <i>see</i> advanced villous maturation
adaptive regulation, 149 <i>see also</i> amino acid transport	anaemia, maternal, 56	AVP, <i>see</i> arginine vasopressin
adolescent pregnancy, 25–6	ancestry-informative gene markers (AIMs), 136	
adrenocorticotrophic hormone (ACTH), 19	androgenetic embryo, 75	
advanced villous maturation (AVM), 203 placental symmetry, 204	Angelman syndrome, 91 and ART, 91	
AGA, <i>see</i> appropriate for gestational age	angiotensin converting enzyme (ACE), 37	
AIMs, <i>see</i> ancestry-informative gene markers	antechamber, 162 functions, 162	
AKT/mTOR signalling, 167	antigenic paternal genome, 103	
allostasis, 19	antioxidant molecules, 51	
alpha-fetoprotein (AFP), 192, 199	appropriate for gestational age (AGA), 115 <i>see also</i> small for gestational age	
amino acid transport factors involved, 155 sodium-dependent transporter, 148, 149, 153 sodium-dependent transporter stimulators, 149 sodium-independent transporter, 148, 149	aquaporins, 21	
amino acid transporters and fetal size, 150 and IUGR, 150 large babies placentas, 154 placenta receptors, 151 regulation, 151 sodium-dependent transporter, 160 trophoblast regulators, 150	areal density, 217	
	arginine cardiovascular adaptations, 27 conditionally essential amino acids, 26 inter-organ co-operativity, 27 <i>see also</i> glycine	
	arginine vasopressin (AVP), 21–2 activation, 21 on liver, 21 nitrogen balance, 21 on placenta, 21 role, 21	
	ART, <i>see</i> assisted reproductive technologies	
	arterial O ₂ concentration (CaO ₂), 130–1 altitude impact, 127 determinants, 130	
		basal plasma membrane (BM), 148
		BAT, <i>see</i> brown adipose tissue
		Beckwith-Wiedemann syndrome, 91
		β-cells proliferation, 85–6
		bilaminar embryonic disk, 50 <i>see also</i> amniotic cavity; yolk sac
		binucleate cells (BNC), 178 placental lactogen level, 180
		birth weight adult bone mass, 218–19 adult bone strength, 220 adult longevity, 175 altitude and resident time, 128 altitude impact, 127, 126–9 altitude vs. surname analyses, 135, 135–6 blood pressure, 7, 7 and diseases, 22, 114, 175 infant survival, ischemic heart disease mortality, 201 as marker, 5 mTOR signalling, 154 placental weight, 115 risk factors, 1, 5, 20, 201

Index

- socio-economic status, 128
triglycerides, 159
- blood
factors affecting flow, 132
placental impact on pressure, 8–9
pregnancy impact on volume, 131
- blood pressure, mean systolic, 7
- BM, *see* basal plasma membrane
- BNC, *see* binucleate cells
- bone
calcium regulation, 227
density and PMCA3, 227
density, geometry and strength, 219
in utero growth, 217–18
infancy weight and femoral geometry, 219
mass, 216
mass and birth weight, 218–19
mass and maternal vitamin D, 221
mass and PMCA3 expression, 224
maternal nutrition, 218
strength and birth weight, 220
strength and infancy weight, 220
- brain, 194
DLK1 neurogenesis, 91
epigenetic programming, 91
perfusion and SGA fetuses, 118
- brown adipose tissue (BAT), 85
- buffering, 46
- C¹⁴-methyl amino-isobutyric acid (MeAIB)
across placenta, 180
small *Igf2P0* null placenta, 181
system A, 148
- cancer
pre-eclampsia, 14
tumor suppressor gene, 64
see also lung cancer; placental area
- cardiometabolic syndrome, 25
- cardiomyocytes
embryonic, 209
factors affecting, 3, 10
fetal heart, 209, 210
heart growth, 208, 211
heart vulnerability, 208
- cardiovascular disease
offspring hypertension, 15
placenta, 14
placental growth, 7
- cardiovascular system
endothelium development, 208
- heart features, 208
stress effect, 208
vasculature, 208
- caruncles, 210
- CE, *see* coelomic fluid
- chondrocyte proliferation, 218
- chorion
endometrial interaction, 172
frondosum, 163
- chorionic cavity, *see* exocoelomic cavity
- chorionic fluid, *see* coelomic fluid
- chronic diseases
heart failure, 10
lung disease, 146
5-L-oxoprolinuria, 27
pattern, plasticity, 35
- coelomic cavity, 55
- coelomic fluid (CF), 50
antioxidant molecules, 51
- compensatory placental growth, 5, 9, 10, 46
hypertension, 11
inadequacy effect, 9
pre-eclampsia, 6
- compensatory processes, 46
- conceptus
androgenetic, 74
in compromised environment, healthy development, 18
maternal nutritional state, 18
nutrient supply factors, 18
nutrients, 18
parthenogenetic/gynogenetic, 74
see also syncytiotrophoblast
- coronary artery disease prevalence, 215
- coronary heart disease
placental impact, 9
SMR, 206
- cytotrophoblast, 49
layer, 102
shell functions, 48
- decidua
B cells, 106
basalis, 105
erosion, 93
function, 109
leukocytes, 105, 106
macrophages, 106
- NK cells, 106
T cells, 106
- decidual glands, *see* endometrial glands
- decidualisation, 46, 98, 105
definition, 105
in human, 96
trophoblast-cell invasion, 105
- developmental delay, 87
- 'Developmental Origins of Health and Disease' (DOHaD), 35, 57
Cited1 model, 66
Esx1 model, 66
Igf2P0^{+/-} model, 65
imprinted genes, 65
mouse IUGR models, 67
oocyte maturation, 36
Phlda2 KO and Tg mice, 63
Phlda2 over-expression model, 66
plasticity, 35
- developmental plasticity, 222
- developmental programming
after birth, 233–4
cardiovascular disease, 208
and clinical evidences, 234
and Darwin's paradigm, 235
environmental signals, 234
extra-placental routes, 233
fracture risk, 224
implications, 168
imprinted genes, 74
key factors, 233, 235
mechanisms, 9
non-placental candidates, 233
placental differences, 233
sex impact on, 186
see also developmental plasticity
- dexamethasone
leptin expression, 180
PGE2 production, 181
umbilical lactate uptake, 179
vasculature, 186
- diet, poor, 25
preimplantation, 39–41
- differentially methylated regions (DMRs), 77
secondary/somatic, 77
- DMRs, *see* differentially methylated regions
- DNA methylation, 77, 222
as epigenetic processes, 22
folic acid impact, 222
functions, 37
gene regulation, 34
in humans, 223

Index

- DNA methylation (*cont.*)
osteoporosis epigenetics, 221
in preimplantation development, 37
see also histone modification;
imprinted genes; non-coding
RNA
- DNA methyltransferases (Dnmt),
222
- Dnmt, *see* DNA methyltransferases
- DOHaD, *see* 'Developmental Origins
of Health and Disease'
- Down's syndrome
AFP level, 199
detection issues, 194
- dual energy x-ray absorptiometry
(DXA), 217
- dually-perfused circuit, 134
- DXA, *see* dual energy x-ray
absorptiometry
- ECC, *see* exocoelomic cavity
- 'echoic cystic lesions', *see* 'placental
lakes'
- Emb-LPD model, 38
- embryo
active, 24
androgenetic, 75
blood flow pattern effect, 208
culturing effect, 91
gender based responses, 45
interaction with environment, 40
maternal diet impact, 39–41
nutrient supply, 55
over-growth, 81
parthenogenetic/gynogenetic, 74
preimplantation in human, 41
quiet, 24
transfer, 46
- emphysema mortality, 146
- endochondral ossification, 217
- endocytosis, gestational
LPD impact, 41
yolk sac role, 39
- endometrial glands
conceptus survival, 56
first trimester, 48
functions, 48, 49
second trimester, 48
secretions, 48
'uterine milk', 49, 56
- endometrium, 105
chorion interaction, 172
NK cells, 172
- uNK cells, 106
see also decidualisation
- endoplasmic reticulum stress, 166–7
- epidermal growth factor, 49
- epigenesis, 22–3
developmental plasticity, 224
epigenetic mark, 75
human disease mechanism,
222–3
see also DNA methylation
- epigenetic regulation
gene methylation, 147
placental calcium transfer,
223
- epigenetic reprogramming
at embryo, 78
environmental modulation, 79–80
after fertilization, 78
in utero undernourishment, 79
in vitro embryo culture, 79
low protein diet, 79
pre-implantation, 78–80
at primordial germ cell, 80–1
uterine environment effect, 78
at zygote, 78
- epigenetics, 221
- ER stress, 173
ER homeostasis, 137
on placental function, 168
placental transporter activity, 168
- essential amino acids, conditionally, 19
functions, 26
metabolic interactions, 27
- 'eutherian' mammals, *see* 'placental
mammals'
- EVT, *see* extravillous trophoblast cells
- exocoelomic cavity (ECC), 50, 54
coelomic fluid, 50
materno-embryonic transfer
activity, 50
- extra-embryonic lineages, 39, 40
- extra-embryonic tissues
in androgenetic conceptus, 75
imprinted genes, 81
in parthenogenetic/gynogenetic
conceptus, 74
- extravillous trophoblast cells (EVT),
47, 102
HLA-B + A expression,
interstitial invasion, 93
mRNA for PAPP-A, 191
spiral artery conversion, 163
types, 102
- see also* placentation;
syncytiotrophoblast;
trophoblastic plugs
- fAd, *see* full-length adiponectin
- fat diet model, high, 154
- femoral geometry and infancy weight,
219
- fetal cortisol
concentration effects, 176
developmental programming, 186
glucose uptake, 179
MeAIB uptake, 179
placental amino acid delivery, 179
- fetal growth, 115
abnormality indicator, 114
altitude-associated reductions scans,
137
amino acid, 147
amino acid transporters in altered,
149
feto-placental O₂ consumption,
139–41
imprinted placental genes' role,
155
kidney's role,
- Fetal Growth Restriction (FGR), 114
gene deletion effect, 177
impact on gender, 205
mTOR activity, 154
protection against, 144
trophoblast invasion, 103
- fetal heart
developmental regulators, 210–11
sensing hemodynamic force, 209
- fetal heart rate (FHR), 119
- fetal nutrition
demand anticipation, 18
diet variation impact, 20
factors affecting supply, 152
hypertension, 11
impact on development, 24
maternal diet, 21
nutrient prerequisites, 18
undernutrition, 22
- fetal programming, 5
amino acid, 147
amino acid transport role, 154
chronic diseases, 5
decidualisation, 105
early steps' importance,
gastrulation,
geographic prevalence,
HLA-C, 107
KIR, 107

Index

- meternal immune response in, 102
- NK cells receptor, 106–7
- u NK cells, 106
- see also* developmental programming
- fetus
- adaptation, 125
 - adolescent pregnancy, 33
 - adult diseases, 57
 - Cdkn1c* expression, 61
 - Cited1* deficient placenta, 64
 - developmental plasticity, 74
 - developmental programming, 1, 4, 167
 - DNA in maternal serum, 200
 - epigenetic alterations, 74
 - Esx1* deficient placenta, 64
 - fatty liver, 207
 - feed back, 125
 - gestational diabetes on weight, 15
 - Grb10* expression, 62
 - head circumference vs. AIMS
 - hypoxia, 116–17
 - Igf2r* expression, 62
 - nutrient sensor, 3
 - nutritional impact, 8, 9, 10, 11, 22
 - oxygen requirement, 55
 - Peg1/Mest* expression, 62
 - Peg10* role, 63
 - Peg3* deletion, 63
 - placenta size, 14, 71
 - placental mitochondrial DNA vs. umbilical pO₂, 118
 - Plagl1* deletion, 63
 - reduced aminoacid, 15
 - resource limitation for, smoking mother, 26
 - thyroid hormone production, 55
 - under-oxygenation, 144
 - Zac1* growth promoter, 64
- FHR, *see* fetal heart rate
- fibroblasts, 45
- see also* trophoctoderm
- full-length adiponectin (fAd), 149
- gastrulation,
- gene expression
- DNA methylation, 37
 - fetal undernutrition, 22
 - IGF2* expression, 64
 - in inflammation, 146
 - knockout, 61
 - maternal nutrition, 22
 - methylation, 34
 - over-expression, 63, 61
- Phlda2* expression, 61
- suppression, 63
- gene transcription
- altered phenotype, 23
 - as epigenetic processes, 22
 - silencing, 22
- gene, natural selection signatures, 137
- genomic imprinting, 75, 57, 75
- DNA methylation, 77
 - histone modification, 77–8
 - intra-genomic conflict model, 60
 - non-coding RNA, 78
 - in placenta, 58–60
 - see also* imprinted genes
- gestation
- age and UA blood flow, 132
 - gestational sac, 50
 - length and adult diseases, 100
- glucocorticoid receptors (GR), 20,
- 181
 - distribution, 186
 - expression, 187
 - functions, 20
 - integrated responses, 33
 - maternal grooming, 20
- glucocorticoids, 20–1
- action mechanism, 181
 - amino acid metabolism, 179
 - in cell differentiation, 176
 - feto-placental exposure, 176–7
 - functions, 181–2
 - hormone metabolism, 181
 - intrauterine environmental signal, 175
 - intrauterine programming, 175
 - in late gestation, 175
 - in maternal and fetal circulation, 182
 - maturational signals, 175
 - placental and fetal weights, 178
 - placental development, 177–9
 - placental efficiency, 177
 - progesterone/oestrogen, 180
- glucose
- disposal site, 84
 - umbilical uptake, 179
- glycine, 27
- across placenta, 33
 - conditionally essential amino acids, 26
 - “pacemaker of metabolism”, 27
 - see also* arginine
- glycodelin, 49
- GM-CSF, *see* granulocyte-macrophage colony-stimulating factor
- GR, *see* glucocorticoid receptors
- granulocyte-macrophage colony-stimulating factor (GM-CSF), 37
- GRIT, *see* Growth Restriction Intervention Trial
- growth, 17
- blastocyst expansion, 17
 - factor gene, 57
 - implantation, 18
 - velocity of body length, 217
 - velocity of bone, 217
 - vulnerability period, 17
- Growth Restriction Intervention Trial (GRIT), 119
- haemochorial placentation challenges, 162
- hazard ratio
- for hip fracture, 224
 - pre-eclampsia, 6
- heart, 208
- blood vessel development, 208
 - cell detection, 214
 - developmental features, 208
 - diseases, 208
 - endothelium development, 208
 - growth, 209–10
 - stress effect, 208
- heart attack, *see* myocardial infarction
- hemodynamic force, 209
- hemodynamic signal, 208–9
- hip fracture
- and placental eccentricity, 224
 - placental efficiency, 224
- histiotroph, *see* “uterine milk”
- histone modification, 77–8, 222
- in cancer, 222
 - heritability of, 78
 - in programmed tissue, 67
 - and transcription, 23
 - see also* DNA methylation; imprinted genes; non-coding RNA
- HLA, *see* human leucocyte antigen
- ‘hose-pipe’ effect, 167
- HPA, *see* hypothalamo-pituitary-adrenal
- human chorionic gonadotrophin (hCG), 192
- human evolution, immunological perspective,

Index

- human leucocyte antigen (HLA),
 - 104–5
 - against HIV,
 - HLA-C, 107
 - HLA-C and reproductive success,
 - 107–8
 - in human evolution,
- hypertension
 - fetal nutrition, 11
 - mothers' height, 9
 - odds ratio, 11
 - offspring cardio vascular risk, 202
 - placental area, 8, 9, 8
 - sex difference and placental weight,
 - 11
- hypothalamo-pituitary-adrenal (HPA),
 - 17
 - Avp* role, 21
 - axis prepartum activation, 176
- hypoxemia
 - cardiac cell numbers, 210
 - IUGR, 210
- hypoxia
 - cardiac cell enlargement, 145
 - intermittent, 140
 - reperfusion and spiral artery
 - conversion, 171
 - reperfusion injury, 125
 - uterine vessels' growth, 134
 - vascular responses, 145
- I/R injury, *see* ischemia/reperfusion injury
- IAPs, *see* intra-cisternal A particles
- ICRs, *see* imprinting control regions
- IGF, *see* insulin like growth factors
- IGFBP, *see* insulin-like growth factor binding protein
- Ig-SF receptors, *see* Ig-superfamily receptors
- Ig-superfamily receptors (Ig-SF receptors), 106
- impedance, 209
- implantation
 - blastocyst orientation, 164
 - human, 161
 - placental site, 189
 - uterine cornuae, 165
 - variations, 161
- imprinted genes, 74, 151
 - on adipose tissue, 84–5
 - adult diseases, 87
 - arrangement, 75
 - β -cells proliferation, 85–6
 - chromosomal locations, 58
 - Cited1* model, 66
 - DNA methylation, 57, 60
 - DOHAD models, 65
 - dosage sensitive, 87
 - Esx1* model, 66
 - functions, 57, 81–7
 - homeostasis control, 82
 - Igf2* knockout, 83
 - Igf2* placental-specific model
 - possibility, 67
 - Igf2* role, 87
 - Igf2P0^{+/-}* model, 65
 - IUGR, 64–5
 - monoallelic restriction, 87
 - multiple, 60–4
 - neonatal diabetes, 86
 - neurological disorders, 91
 - parental imprinting, 57
 - Phlda2*, 62
 - Phlda2* marker, 71
 - Phlda2* over-expression model, 66
 - in placenta, 58–60
 - polymorphism, 91
 - psychiatric diseases, 86
 - role of, 74, 75
- imprinting, 74, 136
 - and ART, 41
 - brain's scope, 91
 - defect, 72
 - and histone modification, 60,
 - 77–8
 - intra-genomic conflict model, 60
 - IUGR, 65
 - loss of, 61, 62, 85, 87
 - monoallelic expression, 57
 - mutations, 71
 - in placenta, 59
 - placentation, 81
 - see also* genomic imprinting
- imprinting control regions (ICRs), 75
 - 12 Dlk1-Dio3 domain, 77
 - categories, 77
 - DNA methylation reprogramming, 80
- in utero*
 - drug effect, 174
 - stress impact, 86
- in vitro* culture (IVC), 36
 - GM-CSF, 37
- in vitro* maturation (IVM), 36
 - long term effects, 36
- inhibin A and pre-eclampsia, 193
- insulin like growth factors (IGF), 191
 - functions, 191
- insulin-like growth factor binding protein (IGFBP), 191
- insults, 3
 - impact on generations, 199
- intergenerational communication
 - consequence, 20
 - epigenetic factor, 20, 22
 - glucocorticoid's role, 20
- intermittent perfusion, 165
- intervention studies,
- intervillous circulation, 47–8
- intervillous space blood pressure, 162
- intra-cisternal A particles (IAPs), 80
- intra-genomic conflict model, 60, 61
- intramembranous ossification, 217
- intrauterine environmental conditions,
 - 175
- intrauterine fetal death, 119
- intrauterine growth restriction (IUGR), 64
 - acidemia, 117
 - amino acid level, 149
 - amino acid transporters, 149
 - amino acid uptake, 119
 - blood flow, 124
 - BM calcium pump, 150
 - brain damage susceptibility, 119
 - clinical relevance, 114–15
 - etiology, 115
 - fatty acid level, 159
 - fetal adaptation, 125
 - fetal signal, 159
 - head circumference, 124
 - hypoxia, 117
 - Igf2* knockout mice, 124
 - imprinting defect, 72
 - monitoring, 119–20
 - placental mitochondrial DNA vs. umbilical pO₂, 118
 - placental phenotype, 117
 - reduced *Igf2* expression, 83
 - reduced nutrient uptake, 116
 - severity classification, 120
 - thyroid impact, 211
 - triglyceride level, 159
 - see also* Fetal Growth Restriction
- ischaemia reperfusion
 - episodes, 165
 - hypoxia, 172
- ischemia/reperfusion injury (I/R injury), 140
- IUGR, *see* intrauterine growth restriction

Index

- IVC, *see in vitro* culture
- IVM, *see in vitro* maturation
- junctional zone, 99
- Killer Immunoglobulin receptors (KIR), 106, 107
AA and pregnancy, against HIV, in human evolution, reproductive success, 107–8
- KIR, *see* Killer Immunoglobulin receptors
- knockout (KO), 57, 61
HOXA13mice, 209
Igf2, 83
liver-specific *Igf1*, 158
TNF receptor impact, 73
- KO, *see* knockout
- large offspring syndrome (LOS), 36
- LDL receptor functions, 39
- LOS, *see* large offspring syndrome
- low protein diet (LPD)
effects, 158, 222
model, 153–4
osteoporosis, 221
- lung cancer
amino acid level, 10
placental impact, 10
short at birth, 10
- macrophages, 45
see also trophoctoderm
- Major Histocompatibility Complex (MHC), 106
antigens, 104
- mammalian target of rapamycin (mTOR), 147
complexes, 150
protein translation, 150
signalling, 3, 153, 154
- maternal
BMI and neonatal fatty acid, 207
care and plasticity, 35
and embryonic transfer activity, 50
fetal blood flow, 116
fetal boundary formation, 102
fetal exchange, 48, 57
fetal interface, 49
grooming effects, 20
nurturing behaviour and *Peg3*, 73
- nutrition and placental sensitivity, 207
obesity, 33
obesity consequences, 35, 207
oestrogen on offspring, 227
perfusion, 93
placental-fetal phenotypes, 9, 10
plasma with antioxidant molecules, 51
pre-conceptual nutrition, 206–7
- maternal immune response
decidualisation, 105
HLA, 104–5
HLA-C, 107
KIR, 107
NK cells receptor, 106–7
u NK cells, 106
uterine mucosal lymphocytes, 105–6
- maturational signals, 175
- metabolic axis control, 86–7
- MHC, *see* Major Histocompatibility Complex
- microvillous plasma membrane (MVM), 148
- mid-gestational lethality, 81
- miscarriages
pheochromocytoma, 173
reasons, 55
trophoblast invasion, 100
- mitochondrial DNA (mtDNA), 129
- mtDNA, *see* mitochondrial DNA
- mTOR, *see* mammalian target of rapamycin
- muscle pump, *see* fetal heart
- MVM, *see* microvillous plasma membrane
- myocardial infarction, 208
- neonatal diabetes, 86
- nitrogen balance, 21
- NK cells receptor, 106–7
- non-coding RNA, 78
see also DNA methylation; histone modification; imprinted genes
- non-imprinted gene IUGR models, 67
- non-shivering thermogenesis (NST), 85
- NR, *see* nuclear receptors
- NST, *see* non-shivering thermogenesis
- nuclear receptors (NR), 119
- nutrients
essential, 19
factors affecting supply, 152
protected pathways, 19
as stressors, 19
- nutrition, 26
adolescent pregnancy, 34
conditionally essential amino acids, 26
demand in pregnancy, 26
endogenous formation, 26
follicle development, 36
gender selection, 24
genome activation, 45
histiotrophic nutrition, 48
integrated responses, 33
IUGR fetus, 119
low protein diet, 32
maternal-fetal blood flow, 116
metabolic interaction, 23
metabolic stress consequences, 25
periconceptual undernutrition, 38
placental transport, 179–81
poor maternal diet, 39–41
preconceptual, 32
preimplantation development, 38
prepregnancy obesity, 25
undernourishment, 36
uterine – umbilical blood flow, 116
villi surface, 115
- obesity
effects on pregnancy, 25
factors, 33
maternal, 33, 35, 207
pregnancy, 154
prepregnancy, 25
- odds ratio
men, 11
women, 11
- oocyte donation and pre-eclampsia,
- ossification, 217
- osteoblasts, 217
- osteoid matrix, 217
- osteoporosis, 216, 224
developmental origins, 216, 221
epigenetic mechanisms, 221–2
- over-expression, 61, 71
- oxidative stress
apoptotic cascade activation, 164
causes, 165
placental, 166
on placental function, 168
placental shape, 172

Index

- oxidative stress (*cont.*)
 vascular regression, 214
 vasoconstriction, 169
 villi regression, 169, 173
- oxygen
 altitude impact, 126–7
 delivery normalization 143n.4
 fetal hypoxia, 116–17
 high altitude fetus, 138
 hypoxia–reperfusion injury, 125
 maternal–fetal blood flow, 116
 supply chain, 126
 umbilical pO₂, 116
- oxygen consumption (VO₂), 138
 fetoplacental oxygenation, 139, 139–41
 at high altitude, 139
- oxygen saturation SaO₂
 high altitude neonate, 138
 subacute infantile mountain sickness, 145
- P/F ratio, *see* placental/fetal weight ratio
- PAMP, *see* Pathogen-associated Molecular pattern
- pancreas, 85
Igf2 role, 85
 neonatal diabetes cause, 86
Neuronatin role, 86
- PAPP-A, *see* pregnancy associated placental protein-A; pregnancy associated plasma protein-A
- parental imprinting, *see* genomic imprinting
- parthenogenetic/gynogenetic embryo, 74
- Pathogen-associated Molecular pattern (PAMP), 104
- PCU, *see* periconceptual undernutrition
- PE, *see* primary endoderm
- peak bone mass, 217
 hereditary, 216
 and strength, 224
- periconceptual undernutrition (PCU), 38
 effects, 38–9
- perinatal mortality
 Doppler flow velocimetry, 190
 IUGR, 120
Peg3 loss and, 87
 placental maturity, 189
- perinatal stressors, 201
- peripheral computed tomography (pQCT), 219
- PGCs, *see* primordial germ cells
- PI, *see* pulsatility index
- placenta, 60, 103, 211
 abnormal placentation, 6, 14
 adaptiveness, 3, 5
 adult diseases, 115
 altitude impact, 140, 168
 amino acid transport, 118–19, 123, 147–8, 149–52, 158
 amino acid transporters, 148–9
 anatomical study, 47
 arterio-venous fistula, 140
 basal plate, 93
 bloodflow geometry, 99
 calcium acquisition, 218
 chorion frondosum, 163
 circulation, 2–3, 47–8, 116, 168
 circumvallate, 174
 compensatory growth, 7, 9
 cross-sections, 94
 damage, 116
 demand anticipation, 27
 development and glucocorticoids, 177–9
 diabetic, 73
 dual perfusion, 117
 eccentricity and hip fracture, 224
 efficiency, 7, 71
 endocrine function, 84, 180–1
 endometrium and, 2
 energy consumption, 60
 exocoelomic cavity, 50
 factors affecting development, 1, 2
 on fetal growth, 19
 as fetal tissue,
 fetoplacental integration, 159
 fetus feed back, 125
 function assessment, 3
 functions, 1, 3, 17, 18, 20, 47, 54, 116, 233
 gender difference, 10, 205
 glucocorticoid exposure, 176–7
 glucose, 10, 179, 118, 158
 GR expression, 20
 in heart development, 211
 historical record, 18
 hormone, 149, 151
 human fibroblasts, 45
 human IUGR, 73
 human macrophages, 45
 hypertension, 1, 8–9
 IGF1regulator, 159
 imaging, 19
 imbalanced free radicals, 47
 immune barrier, 147
- implantation, 116
 insufficiency, 159
 insulin signalling, 149–50
 insults, 3, 16
 intermittent perfusion, 165
 invasion, 100, 101
 maternal factors, 2, 3, 5, 7, 19
 and maternal immune system, 103
 metabolic control, 147
 mitochondrial DNA vs. umbilical pO₂, 118
 morphology, 177–9
 mTOR, 207
 nutrient demand, 18
 nutrient sensor, 3, 5, 152, 118, 152–3, 155, 207, 210
 nutrient transport, 18, 100, 179–81, 202
 effect on offspring health, 207
 oxidative stress, 214
 Phlda2 protein, 72, 73
 placentomegaly, 61, 62
 polarisation, 6, 15
 prednisolone's effect, 186
 pre-eclampsia, 6
 primitive metabolic pathways, and programming,
 pro-inflammatory cytokines, 207
 'pseudo-labyrinthine', 92
 receptors, 151
 rodent models controversy, 100, 101
 secondary yolk sac, 51
 shape, 5–6
 size, 5, 7, 6, 56, 72, 73
 structure, 59
 syncytiotrophoblast, 47
 system A activity study, 215
 thicker, 167
 trophoblast invasion, 2
 VEGFR-1, 192
 venous equilibrators, 116, 140
 volume, 19
 weight, 1, 14
- placenta creta, 103
- placenta previa, 189
see also implantation; placentation
- placenta, human
 abnormalities, 47
 development, 49–50
 spiral artery, 94
- placental
 adaptation, 83
 barrier, 148
 calcium transport, 223, 223, 227
 calcium transporter gene, 223
 homeostatic pathways, 3
 hyperplasia, 81
 impaired development effects, 161

Index

- inadequacy, 202
- infarcts, 15
- lesion, 189
- maturity, 189
- morphology, 177
- nutrient transport, 150
- nutrient transport regulation, **151**
- oxidative stress, 166
- oxygen delivery, 144
- phenotype, small, **167**
- symmetry, 204
- uptake regulation, 119
- vasculature and heart growth, 209
- volume, 188–9
- placental area
 - amino acid level, 10
 - blood pressure indicator, 9
 - coronary heart disease, 9
 - hypertension, 8, 9, **8**
 - lung cancer, 10
 - mother's height, 8
- placental development
 - abnormal maternal blood flow, 165–7
 - failure consequence, 61
 - Igf2* gene, 181
- placental efficiency, 7, 99
 - biological constraints, 99
 - Dutch famine, 8
 - glucocorticoid's role, 177
 - hip fracture, 224
 - maternal body composition, 15
 - Ramadan eating pattern, 7–8
- placental growth, 115
 - Igf2P0*, 83
 - imprinted genes, 57
 - maternal nutrition, 19, 26, 205
 - meternal anaemia, 56
 - multiple imprinted genes, 60–4
 - Phlda2*, **62**
 - Phlda2/lpl* expression, 83
 - restriction, 177
 - sex difference, 10–11
- placental growth factor (PLGF)
 - pre-eclampsia, 192, 193
 - SGA, 193
- placental insufficiency, 114, 115–19, 120
 - animal models, 210
 - etiology, 115, 209
 - genetic model possibility, 67
 - histological features, **204**
 - human, 203–6
 - IUGR, 81, 114–15
 - placental weight, 115–16
 - reverse flow, 209
- placental lacunae, 189
 - see also* trophoblast invasion
- 'placental lakes', 167
- 'placental mammals', 48, 63
- placental programming
 - chronic disease, 11, 12
 - sex difference in, 11
- placental shape
 - abnormality effect, 161, 168
 - determinants, 161
 - impact on gender, **205**
 - human, 161
 - oxidative stress, 172, 173
 - pre-eclampsia, 202–3
 - stable form, 168
 - variations, 161
 - see also* placental surface
- placental size
 - blood pressure, 9
 - cardiovascular risk, 201
 - compensatory growth, 211
 - mother's birth weight, 15
 - offspring disease/hypertension, 211
 - pre-eclampsia, 6
 - uterine blood flow, 7
- placental surface, 1
 - blood pressure, 9
 - chronic heart failure, 10
 - disease predictor, xi
 - function, 5
 - hypertension, 9
 - malnutrition indicator, 9
 - pre-eclampsia, 6
 - transfer capacity, 115
- placental thickness, 8, 14
 - gestational age, 188
 - see also* pre-eclampsia
- placental weight, 3, 7
 - abnormalities, 115–16
 - adult diseases, 202
 - gender difference, 10
 - and glucocorticoids, 177
 - hypertension, 5, 7, 8, 9, 11, 116
 - hypotension, 7
 - mean systolic blood pressure, 7
 - see also* birth weight; placental thickness
- placental/fetal weight ratio (P/F ratio), 115
- placentation, 172
 - abnormality, 101
 - AFP, 192
 - angiogenesis associated proteins, 192–3
 - assessment, 188–9, 194–5
- biochemical markers, 191–4
- decidua basalis, 105
- defect indicator, 192
- driving forces, failure cause, 81
- hCG, 192
- HLA-C antibody, imprinting role, 81
- as indicator, 188
- KIR:HLA-C interaction, 107–8
- optimal development, 96
- PAPP-A, 191–2
- placenta derived proteins, 193–4
- preconceptual nutrition, 32
- regulatory T cells, 105
- trophoblast invasion, 189
- upright gait, 108
- see also* haemochorial placentation
- challenges; trophoblast invasion
- placentomegaly, 61, 62
- placentomes, 179, 210
- PLGF, *see* placental growth factor
- polymorphic genes in reproduction, 108
- POP assessment, 195
- postpartum depression and maternal nutrition,
- pQCT, *see* peripheral computed tomography
- Prader-Willi syndrome, 91
- pre-eclampsia, 6
 - abnormal flow-mediated dilatation, 199
 - ADAM12, 193
 - adult diseases, 198
 - AFP-PAPP-A indicator, 200
 - angiogenesis associated proteins, 192–3
 - anorexic mothers, 124
 - cancer, 14
 - Cdkn1c* deficiency, 61
 - "dangerous" males, effects, 116
 - genetic cause, 103
 - hazard ratios, 6
 - hCG, 192
 - immune recognition, 103
 - impaired invasion, 92, 95, 96, 97
 - IUGR, 96
 - marker's scope, 200
 - maternal cardiovascular risk, 124
 - maternal endothelial damage, 124
 - maternal low birth weight, 124
 - offspring cardio vascular risk, 202
 - oocyte donation,

Index

- pre-eclampsia (*cont.*)
 oxidative stress, 133
 PAPP-A, 191, 193
 placental oxidative stress, 166
 placental shape, 202–3
 placental volume, 188
 PIGF, 193
 pre-pregnancy Doppler, 199
 pulsatility index, 190
 risks, 103
 triglycerides level, 159
 trophoblast invasion, 102, 103, 124
 UA Doppler, 199, 200
 UPI vs. normal placenta, **206**
 utero-placental haemodynamics, 173
see also placental size
- pregnancy
 adolescent, 25–6, 33, 34
 arginine's role, 27
 AVP sensitivity, 21
 blood volume, 131
 complications, 162, 188, 194
 decidual erosion, 93
 dexamethasone role, 47–8
 glucocorticoids, 20, 177
 GR promoters, 23
 high metabolic demand, 26
 HLA, 104–5
 HPA axis stress response, 20
 immunology of, 103–4, 108
 intergenerational communication, 20
 IUGR, 114
 leukocytes, 105
 low protein diet, 23
 macrophages, 106
 maternal diet impact, 24
 maternal obesity, 154
 micronutrient supplements, 33
 mothers' preparation, 109
 normal features, 18
 nutritional metabolic stress, 25
 overnourishment, 26
 5-L-oxoprolinuria, 27
 placental blood flow, 163, 168
 and safety factor,
 smoking, 26
 as stress, 19
 UA blood flow, 133, 131, 140
 UA diameter, 131
 vasoactive substances, 133–4
- pregnancy associated placental
 protein-A (PAPP-A), 3
 femur length, 194
- pregnancy associated plasma
 protein-A (PAPP-A)
see also activin A
- preimplantation
 development, 37
 Emb-LPD model, 38
 IVC effects, 36–7
 LOS, 36
 maternal nutrition, 38
 mono-allelic gene expression, 37
 post-fertilisation cleavage, 36
 undernourishment, 36
- prenatal diagnosis limitation, 55
- prepregnancy obesity, 25
- primary endoderm (PE), 39
- primordial germ cells (PGCs), 80
 imprint reacquisition, 80
- principle component (PC)
 analysis, 129
 SNP, **129**
- protein synthesis inhibition, **167**
- puberty delay etiology, 87
- pulsatility index (PI), 119
 flow resistance, 190
 pre-eclampsia prediction, 190
 SGA infant, 190
- reactive oxygen species (ROS), 140
- reproduction
 histo-incompatibility, 103–4
 HLA-C and KIR, 107–8
 KIR AA effect, 108
 maternal receptor significance, 108
 polymorphic genes, 107–8
- ROS, *see* reactive oxygen species
- SaO₂, *see* arterial O₂ saturation
- SCOPE assessment, 195
- secondary yolk sac (SYS), 50
 coelomic fluid, 54
 formation, 51
 functions, 51–2
 serum proteins, 51
- sEng, *see* soluble endoglin
- sFlt-1, *see* soluble fms-like tyrosine kinase 1
- SGA, *see* small for gestational age
- short mothers
 amino acid level, 10
 amino acid synthesis, 8
 hypertension, 8
 lung cancer, 10
 systolic pressure, 9
see also lung cancer; tall mothers
- Signal Transducer and Activator of Transcription [3] (STAT3), 149
- 'silent period', 234
- single nucleotide polymorphism (SNP), 129
 principle components, **129**
- skeletal development, 217–18
 factors affecting, 219–21
- skeletal recovery, 228
- small for gestational age (SGA), 64, 114, 190
 brain perfusion, **118**
 hCG, 192
 placental volume, 188
see also intrauterine growth restriction
- SMR, *see* standardised mortality ratios
- SNP, *see* single nucleotide polymorphism
- soluble endoglin (sEng)
 pre-eclampsia, 192, 193
 SGA, 193
- soluble fms-like tyrosine kinase 1(sFlt-1), 192, 193
- Southampton Women's Study (SWS), 195
- spiral arteries, 173
 alternative nutrition source, 163
 anatomy, 162
 antechamber, 162
 bipedalism, 97
 blood flow, 162
 cross-sections, **94**
 erosion, 99
 fate of, 174
 functions, 161
 haemochorial placentation, 162
 'hose-pipe' effect, 167
 invasion, 95
 myometrial sections, **95**
 placental efficiency, 99
 placentation, 6
 and pregnancy, 162
 research scope, 14
 velocity, 173
 villus-free cavity, 162
- spiral artery conversion, 162, 163, 165, 172
 deficiency, **168**, 163, 165, 167
 impact on placenta,

Index

- standardised mortality ratios (SMR), 206
- STAT3, *see* Signal Transducer and Activator of Transcription [3]
- stem cell differentiation, mesenchymal, 218
- stillbirth
AFP and hCG, 199
gender impact, 198
hCG, 192
risk analysis, 190
trophoblast invasion, 103
- stress
allostasis, 19
diet variations, 20
GR expression, 20
hormonal responses, 19
in periconceptual period, 20
regulatory genes, 23
response, 20
- stressors, 17
- subacute infantile mountain sickness, 145
- superficial fibrinoid layer, 100
- surname analysis, 135
- SWS, *see* Southampton Women's Study
- syncytiotrophoblast, 47, 49
glucose transporters, 55
- SYS, *see* secondary yolk sac
- system A, *see* amino acid transport
- system L, *see* amino acid transport
- tall mothers
hypertension, 8
placental area, 9
systolic pressure, 9
see also short mothers
- TAM, *see* time-averaged mean velocity
- TE, *see* trophoctoderm
- TGF- β , *see* transforming growth factor β
- "Thrifty phenotype", 74
- thyroid hormones regulation, 87
- time-averaged mean velocity (TAM), 131, 131n.3
- TNF- α , *see* Tumor Necrosis Factor-alpha
- tocopherol transfer protein, 49
- toxaemia and cardiovascular risk, 15
- 'trabeculae', 92
- transforming growth factor β (TGF- β), 193
- "tri-mark", 78
- trophoctoderm (TE), 39
blastocoel, 45
blastocyst differentiation, 39
endocytosis, 39–40
maturation, 39
nutrient sensing, 40
see also fibroblasts; macrophages
- trophoblast
active transport, 55
Cited1 expression, 64
degeneration, 164
extravillous, 163
HLA, 104–5
HLA-C, 107
hormones, properties, 104
sample limitation, sub-populations, 102
transporters, 54
- trophoblast invasion, 2, 92, 93, 99, 100, 140, 162, 189
abnormal, 102–3
altitude impact, 145
blood flow, 124
decidual NK cells, 109
deficiency effect, 165
depth advantages, 95–6
effect of shallow, 165
end points, 100
endovascular, 94–5
factors affecting, 165
function of, 102
junctional zone, 99
maternal alleles role, 100
miscarriages, 100
pattern, 163
pre-eclampsia, 92, 102
prematurity, 103
spiral arteries, 96, 165
- trophoblastic plugs, 48
- Tumor Necrosis Factor-alpha (TNF- α), 149
- UA, *see* uterine artery
- ubiquitous phenomenon, 217
- umbilical
artery Doppler, 190–1, 199
circulation, 54
cord centricity, 14
- umbilicoplacental embolisation, 210
cardiomyocytes activity
see also placental insufficiency
- uniparental disomies (UPDs), 57
- uNK, *see* uterine natural killer cells
- UPDs, *see* uniparental disomies
- UPI, *see* uteroplacental insufficiency
- "uterine", 124n.1
- uterine – umbilical blood flow, 116
- uterine artery (UA), 126, 199
Doppler, 199
enlargement, 134
growth, 134
in twinning, 127
uterine definition, 124n.1
O₂ delivery and VO₂, 139
- uterine artery (UA) blood flow, 131–3, 173
abnormal velocity, 167
AIMs, 136
altitude impact, 139–40
determinants at altitudes, 132
Doppler velocimetry, 189–90
fetal growth, 138–9
feto-placental development, 126
vs. feto-placental oxygenation, 139–41
genome scans, 136–7
I/R injury, 140
intermittent hypoxia, 140
maternal blood viscosity, 162
non-pregnancy *vs.* pregnancy, 133
normalization, 143n.4
vasoactive substances, 133–5
- uterine blood flow, 131
high altitude populations, 3
impact, 26, 152
IUGR fetus, 124
in labour, 166
placental resistance, 116
pre-eclampsia prediction, 173
regulation, 137
see also placental efficiency; placental size
- uterine cornuae, 165
- uterine glands, *see* endometrial glands
- "uterine milk", 48, 54
epidermal growth factors, 49
production, 49
see also endometrial glands
- uterine mucosal lymphocytes, 105–6
- uterine natural killer cells (uNK cells), 92, 106, 107

Index

uterine O ₂ delivery, 130 altitude impact, 130–5 fetal growth, 139–41	vascular resistance, 134	visceral yolk sac endoderm (VYSE), 40, 40
uterine vasculature changes, 162	vasoactive substances at altitudes, 133	vitamin D bone mass, 221 and uterine function, 227
uteroplacental circulation, Doppler, 189–91	VDR, <i>see</i> vitamin D receptor	vitamin D receptor (VDR), 219
uteroplacental insufficiency (UPI), 204, 203	VEGF, <i>see</i> vascular endothelial growth factor (VEGF)	VO ₂ , <i>see</i> oxygen consumption
	VEGFR-1, <i>see</i> vascular endothelial growth factor receptor [1]	VYSE, <i>see</i> visceral yolk sac endoderm
variable risk, 20	villi development, 49–50 hypovascularisation, 178 regression, 164, 163–5 ‘trabeculae’, 92	yolk sac functions, 55 GLUT1 transporter protein, 51 mesenchymal cells, 55
vascular deaths, 208	villous trophoblast, 102	zinc-finger protein, 84
vascular endothelial growth factor (VEGF), 134		
vascular endothelial growth factor receptor 1 (VEGFR-1), 192		